Cogent Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cogent Biosciences sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Cogent Biosciences: 12 sponsored US clinical trials, 4 recruiting.
Cogent Biosciences sponsors 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Gastrointestinal Stromal Tumors, with 1 trials.
Top-decile sponsor footprint
Cogent Biosciences ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
NCT03680560
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03266692
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
NCT03189836
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
NCT02840110
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT02776813
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
NCT02401815
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the Cogent Biosciences pipeline
4 recruiting of 12 indexed (33% open); 2 completed (17%).
Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Advanced Gastrointestinal Stromal Tumors (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cogent Biosciences: open-pipeline peers nationwide
Peers matched on 12 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Cogent Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Cogent Biosciences page
12 registered trials is a research-attention snapshot, not an endorsement of Cogent Biosciences or any single study.
- 4 of Cogent Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Gastrointestinal Stromal Tumors is the condition Cogent Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Gastrointestinal Stromal Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cogent Biosciences pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.